Clinical trial
Prospective Sequential Study of Dose-Escalating 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07363486 is registered in ClinicalTrials.gov with First Affiliated Hospital of Fujian Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Sequential Study of Dose-Escalating 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- April 1, 2025
- Completion date
- December 31, 2027
- Enrollment
- 9 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer